NURIX THERAPEUTICS INC (NRIX) Stock Price, Quote, News and Overview
NASDAQ:NRIX - Nasdaq - US67080M1036 - Common Stock - Currency: USD
NRIX Quote, Performance and Key Statistics
NASDAQ:NRIX (5/8/2025, 9:32:35 AM)
9.3
0 (0%)
The current stock price of NRIX is 9.3 USD. In the past month the price increased by 0.43%. In the past year, price decreased by -31.16%.
NRIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.50B | ||
| AMGN | AMGEN INC | 12.87 | 143.70B | ||
| GILD | GILEAD SCIENCES INC | 12.42 | 119.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 110.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 12 | 57.41B | ||
| ARGX | ARGENX SE - ADR | 294.32 | 34.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.02B | ||
| ONC | BEIGENE LTD-ADR | 5.9 | 25.51B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.60B | ||
| NTRA | NATERA INC | N/A | 21.69B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.34B | ||
| BIIB | BIOGEN INC | 7.3 | 16.91B |
Related stock screener links
About NRIX
Company Profile
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 286 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.
Company Info
NURIX THERAPEUTICS INC
1700 Owens St Ste 205
San Francisco CALIFORNIA 94158 US
CEO: Arthur T. Sands
Employees: 284
Phone: 14156605320
NURIX THERAPEUTICS INC / NRIX FAQ
What is the stock price of NURIX THERAPEUTICS INC today?
The current stock price of NRIX is 9.3 USD.
What is the ticker symbol for NURIX THERAPEUTICS INC stock?
The exchange symbol of NURIX THERAPEUTICS INC is NRIX and it is listed on the Nasdaq exchange.
On which exchange is NRIX stock listed?
NRIX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NURIX THERAPEUTICS INC stock?
24 analysts have analysed NRIX and the average price target is 30.84 USD. This implies a price increase of 231.61% is expected in the next year compared to the current price of 9.3. Check the NURIX THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NURIX THERAPEUTICS INC worth?
NURIX THERAPEUTICS INC (NRIX) has a market capitalization of 709.03M USD. This makes NRIX a Small Cap stock.
How many employees does NURIX THERAPEUTICS INC have?
NURIX THERAPEUTICS INC (NRIX) currently has 284 employees.
What are the support and resistance levels for NURIX THERAPEUTICS INC (NRIX) stock?
NURIX THERAPEUTICS INC (NRIX) has a support level at 9.13 and a resistance level at 9.31. Check the full technical report for a detailed analysis of NRIX support and resistance levels.
Is NURIX THERAPEUTICS INC (NRIX) expected to grow?
The Revenue of NURIX THERAPEUTICS INC (NRIX) is expected to grow by 13.33% in the next year. Check the estimates tab for more information on the NRIX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NURIX THERAPEUTICS INC (NRIX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NRIX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NRIX, evaluating the profitability, health, valuation and growth aspects
- NURIX THERAPEUTICS INC (NRIX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NURIX THERAPEUTICS INC (NRIX) Sales and EPS estimates to see what analysts future expectations are.
- NURIX THERAPEUTICS INC (NRIX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NURIX THERAPEUTICS INC (NRIX) Insider and Institutional Ownership to learn about the owners and their transactions.
- NURIX THERAPEUTICS INC (NRIX) Stock Chart to make your own analysis
- NURIX THERAPEUTICS INC (NRIX) Latest news and press-releases to stay up to date.
Does NURIX THERAPEUTICS INC (NRIX) stock pay dividends?
NRIX does not pay a dividend.
When does NURIX THERAPEUTICS INC (NRIX) report earnings?
NURIX THERAPEUTICS INC (NRIX) will report earnings on 2025-07-09, before the market open.
What is the Price/Earnings (PE) ratio of NURIX THERAPEUTICS INC (NRIX)?
NURIX THERAPEUTICS INC (NRIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.8).
What is the Short Interest ratio of NURIX THERAPEUTICS INC (NRIX) stock?
The outstanding short interest for NURIX THERAPEUTICS INC (NRIX) is 19.34% of its float. Check the ownership tab for more information on the NRIX short interest.
NRIX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NRIX. When comparing the yearly performance of all stocks, NRIX is a bad performer in the overall market: 90.07% of all stocks are doing better.
NRIX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NRIX. No worries on liquidiy or solvency for NRIX as it has an excellent financial health rating, but there are worries on the profitability.
NRIX Financial Highlights
Over the last trailing twelve months NRIX reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS decreased by -5.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.88% | ||
| ROE | -43.33% | ||
| Debt/Equity | 0 |
NRIX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to NRIX. The Buy consensus is the average rating of analysts ratings from 24 analysts.
For the next year, analysts expect an EPS growth of -7.02% and a revenue growth 13.33% for NRIX